Have a question?
Please get in touch with our team in case of any queries
THE GLOBAL ATOPIC DERMATITIS TREATMENT MARKET SIZE WAS VALUED AT USD 4.85 BILLION IN 2021 AND IS EXPECTED TO REACH USD 11.34 BILLION BY 2027, GROWING AT A CAGR OF 15.20%.
The Global Atopic Dermatitis Treatment Market Share, Size, & Trends Analysis Report by
- Drug Class: Topical Steroids, Topical Calcineurin Inhibitors, Other class of Drugs
- Gender Type: Men and Women
- Age Group: 18 years and Below & 19 years and Above
- Severity Type: Moderate, Mild, and Severe
- Geography: North America (United States), APAC (China, Japan), and Europe (France, Germany, Italy, Spain & U.K.)
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
ATOPIC DERMATITIS TREATMENT MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (2027) | USD 11.34 Billion |
| Market Size (2021) | USD 4.85 Billion |
| CAGR (2022-2027) | 15.20% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Drug Class, Gender Type, Age Group, Severity Type, and Geography |
| Geographic Analysis | North America, Europe, APAC |
| KEY PLAYERS | LEO Pharma, Pfizer, Sanofi/Regeneron, Novartis, Incyte Corp, AbbVie, Eli Lilly and Company, Japan Tobacco Inc, Maruho Co., Ltd, Otsuka Holdings Co Ltd, Astellas Pharma Inc, and Stiefel Laboratories |
The global atopic dermatitis treatment market was valued at USD 4.85 billion in 2021 and is expected to reach USD 11.34 billion by 2027, growing at a CAGR of 15.20% from 2022-2027. Atopic dermatitis is a chronic, pruritic inflammatory skin condition that typically affects the face (cheeks), neck, arms, and legs but usually spares the groin and axillary regions. Atopic dermatitis, also known as atopic eczema, is a chronic relapsing inflammatory skin condition. Atopic dermatitis is common worldwide. People of all ages, from newborns to adults 65 years and older, live with this condition. Atopic dermatitis is associated with an increased risk of multiple comorbidities, including food allergy, asthma, allergic rhinitis, and mental health disorders. Due to such factors, the atopic dermatitis treatment market is growing immensely during the forecast period.
Atopic dermatitis is the most common type of eczema, affecting approximately 26 million people in the United States. Atopic dermatitis is children's most common skin disease, with prevalence steadily increasing from 8% to 12% in the last two decades. It is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inflammation. This reaction produces a red, itchy rash, most frequently occurring on the face, arms and legs, and the rash can cover significant areas of the body. The rash causes significant pruritus (itching), which can lead to damage caused by scratching or rubbing and perpetuating an ‘itch-scratch’ cycle. Pediatric patients with atopic dermatitis can suffer from sleep disturbances, behavioral problems, irritability, crying, and interference with normal childhood activities and social functioning. Adults with atopic dermatitis also frequently suffer from sleep disturbances, emotional impacts, and impaired social functioning. Arizton estimates that the prevalent cases of atopic dermatitis were high in China, followed by U.S. and Japan in 2020. The increasing prevalence of atopic dermatitis is driving the growth of the atopic dermatitis treatment market.
Atopic Dermatitis Diagnosis
The exact cause of atopic dermatitis is unknown. Currently, no reliable biomarker which can distinguish the disease from other entities. However, the most commonly used biomarker is elevated total and/or allergen-specific serum IgE. The diagnosis of atopic dermatitis is based on the history and physical examination findings. Exposure to possible exacerbating factors, such as aeroallergens, irritating chemicals, foods, and emotional stress, should be investigated. Unfortunately, no specific laboratory findings or histologic features define atopic dermatitis.
Atopic Dermatitis Treatment
Most atopic dermatitis patients are treated with topical therapies, particularly low to mid-potency topical steroids and TCIs. These two classes of drugs constituted nearly all atopic dermatitis prescriptions. Despite their widespread use, existing topical therapies all possess substantial shortcomings:
- Topical corticosteroids, in combination with Vitamin D creams and antihistamines, are the first line of treatment for AD. The topical steroids aim to provide short-term itch relief to break the itch-scratch reflex cycle – the primary cause of reinfection. Although in mild cases, these therapies may be effective, in moderate/severe cases, long-term use (of steroids) tends to do more harm than benefit. Prolonged use damages and dries out the epidermal layer of skin, which, somewhat paradoxically, ends up actually worsening the itch-scratch complex.
- Topical steroids pose a particular concern in pediatric patients due to the risk of systemic absorption, the consequent risk of HPA axis suppression, and potential developmental problems. Chronic use of topical steroids in atopic dermatitis patients is generally avoided.
- Second-line agents include immunosuppressant medications such as topical calcineurin inhibitors, including Pimecrolimus (Elidel) and Tacrolimus (Protopic). Topical calcineurin inhibitors are generally seen as providing less symptomatic improvement than topical steroids and are also associated with some application site burning. In 2005 the FDA placed a boxed warning on the labels of both TCIs regarding a potential increased risk of cancers, especially lymphomas.
- Other treatments include biologics, typically starting with interleukin inhibitors such as tralokinumab-idrm, dupilumab, and nemolizumab.
- Topical treatments include PDE-4 inhibitors such as Crisaborole (Eucrisa) and Difamilast (Moizerto); JAK inhibitors such as Ruxolitinib (Opzelura) and Delgocitinib (Corectim Ointment).
- Oral JAK inhibitors such as Abrocitinib (Cibinqo), Upadacitinib (Rinvoq), and Baricitinib (Olumiant) are used for the treatment of atopic dermatitis.
ATOPIC DERMITIS: CLINICAL TRIALS SCENARIO
The clinical trial portfolio contains 153+ trials in various development phases. Most industry-sponsored drugs in active clinical development for atopic dermatitis are in the Phase II stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for atopic dermatitis have been in the mid-phase of development, with 47% of trials in Phase I/II & II and only 29% in Phase Phase II/III-III.
MARKET DRIVERS & TRENDS
Increasing Adoption for Biological Therapies
Biological therapies such as anti-interleukin antibodies are widely used for treatment in the atopic dermatitis treatment market. With Dupixent being the biologic approved for atopic dermatitis in 2017, there is a demand for therapies with novel MOAs that are less immunogenic than current offerings. Many new classes of therapies are looking to enter the market over the next few years. The biologics such as interleukin inhibitors are making inroads into the atopic dermatitis market owing to better clinical profiles and convenient patient dosing.
Anticipated Launch of Emerging Drugs
A recent wave of biological products prescribed for treating atopic dermatitis will likely create a lucrative opportunity for growth in the atopic dermatitis treatment market. Despite the plethora of therapies currently available to patients with atopic dermatitis (AD), there is still room for improvement within the treatment space. Arizton anticipates the launch of five new agents among the 8MM, including two interleukin (IL) inhibitors (Lebrikizumab; CM-310), one topical Janus kinase (JAK) inhibitor (Delgocitinib), and two topical phosphodiesterase 4 (PDE-4) inhibitors (Roflumilast and JW-100). Launching these late-stage drugs will create an opportunity for growth in the global atopic dermatitis treatment market.
Focus on Novel Drugs with Novel Mechanism
The therapeutic agents targeting the IL-13/IL-31 axis have been proven to be very effective in AD, some are already in the therapeutic armamentarium, and others are in development. Over the next five years, Arizton expects to see a surge of innovation emerging from the research and development pipeline and a range of technology-enabled transformations that will expand the evidence basis for interventions and bring measurable improvements to outcomes.
SEGMENTATION ANALYSIS
- Drug Class: Topical Steroids are expected to account for a significant share of the global atopic dermatitis treatment market under the drug class segment. However, the other drug class is expected to be the fastest-growing segment during the forecast period. Recently approved JAK and interleukin inhibitors are expected to drive the global atopic dermatitis therapeutics market during the forecast period.
- Gender Type: Women are expected to dominate the global atopic dermatitis treatment market by gender type. This is because women have been at greater risk of atopic dermatitis in recent years.
- Age Group: People aged 19 years and above are expected to account for most of the global atopic dermatitis market share by the age group segment.
- Severity Type: Among the severity type, People with mild form are expected to account for a significant share of the global market. However, people with moderate form are expected to be the fastest-growing segment during the forecast period.
GEOGRAPHICAL ANALYSIS
In North America, the United States dominates the global atopic dermatitis treatment market due to the rise in healthcare affordability in the country, a rise in the knowledge and awareness amongst the people, and a rise in technological advancement in this region. However, Japan is expected to grow faster with a high CAGR in the atopic dermatitis drug market due to the rise in access and quality of healthcare, increased awareness about disease management, and rising healthcare expenditure in this region.
COMPETITIVE LANDSCAPE
The global atopic dermatitis treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating atopic dermatitis. The U.S. Food and Drug Administration (FDA) approved the interleukin antibody Dupixent (Dupilumab) for treating atopic dermatitis in 2017. This marked the arrival of interleukin biologics in this treatment landscape. Recently the FDA approved interleukins such as Tralokinumab-idrm (adbry) in 2021, and PMDA approved Mitchga (Nemolizumab) in 2022 for treating atopic dermatitis. Although generic products continue to capture significant atopic dermatitis treatment market share, the arrival of biologics and other targeted therapies indicate a paradigm shift in this therapeutic space through the forecast period.
The emerging therapeutics developed for atopic dermatitis include Lebrikizumab, CM-310, Tapinarof, Roflumilast, Rocatinlimab, and many others. Launching these novel emerging drugs will shift the atopic dermatitis therapeutics paradigm soon. With more than 153 molecules in various stages of development, it is expected that new vendors are likely to enter the market with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating atopic dermatitis.
Companies such as AbbVie, Pfizer, Novartis, LEO Pharma, Sanofi/Regeneron, Incyte Corp, Maruho Co., Ltd, Eli Lilly and Company, Japan Tobacco Inc, and others, etc., are the major players in the global atopic dermatitis treatment market. These players are focused on adopting growth strategies to strengthen their product portfolio.
These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global atopic dermatitis treatment market. Other prominent players operating in the global atopic dermatitis treatment market include Arcutis Biotherapeutics, Kyowa Hakko Kirin, Dermavant Sciences, Vanda Pharmaceuticals, CARA Therapeutics, and many others.
REPORT COVERS
- Detailed overview of the atopic dermatitis treatment market, including disease definition, classification, diagnosis, and treatment pattern
- Overview of the global trends of atopic dermatitis in the eight major markets (8MM)
- Historical, current, and projected patient pool of atopic dermatitis in the eight major markets (8MM) for 2018 – 2027
- In-depth market segment analysis, including products, treatment, and competitor analysis
- Atopic dermatitis treatment market share of the market players, company profiles, product specifications, and competitive landscape
- Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
- Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
- Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Atopic Dermatitis across the complete product development cycle, including all clinical and non-clinical stages
- Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for atopic dermatitis across all clinical stages
- Coverage of dormant and discontinued pipeline projects, along with the reasons across the atopic dermatitis treatment market
- Coverage of significant milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the atopic dermatitis space
SNAPSHOT
The global atopic dermatitis treatment market is expected to grow at a CAGR of approximately 15.20% from 2022 to 2027.
The following factors are likely to contribute to the growth of the global atopic dermatitis treatment market during the forecast period:
- Increasing Demand for Biologics
- Increasing Burden of Allergic Reactions
- Anticipated Launch of Emerging Drugs
Base Year: 2021
Forecast Year: 2022-2027
The report considers the present scenario of the atopic dermatitis treatment market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Vendors
- LEO Pharma
- Company Overview
- Product Offerings
- Pfizer
- Sanofi/Regeneron
- Novartis
- Incyte Corp
- AbbVie
- Eli Lilly and Company
- Japan Tobacco Inc
- Maruho Co., Ltd
- Otsuka Holdings Co Ltd
- Astellas Pharma Inc
- Stiefel Laboratories
Other Prominent Vendors
- Arcutis Biotherapeutics
- Company Overview
- Product Offerings
- Kyowa Hakko Kirin
- Vanda Pharmaceuticals
- Dermavant Sciences
- CARA Therapeutics
- AstraZeneca Plc (AstraZeneca)
- UNION therapeutics
- Asana
- Evelo Biosciences
- BiomX
- AOBiome Therapeutics, Inc.
- Amytrx
- RAPT Therapeutics
- Oneness Biotech
- VYNE’s Therapeutics
- BenevolentAI Ltd
- vTv Therapeutics Inc.
- Botanix Pharmaceuticals Ltd (BOT)
- selectION, Inc.
- Inmagene
- Novan, Inc.
Segmentation by Drug Class
- Topical Steroids
- Topical Calcineurin Inhibitors
- Other Class of Drugs
Segmentation by Gender Type
- Men
- Women
Segmentation by Age Group
- 18 years and Below
- 19 years and Above
Segmentation by Severity Type
- Moderate
- Mild
- Severe
Segmentation by Geography
- North America
- U.S.
- APAC
- China
- Japan
- Europe
- France
- Germany
- UK
- Italy
- Spain
Frequently Asked Questions
How big is the global atopic dermatitis treatment market?
What is the growth rate of the global atopic dermatitis treatment market?
What factors drive the growth of the atopic dermatitis treatment market?
Who are the leading vendors operating in the global atopic dermatitis treatment market?
Which region holds the largest global atopic dermatitis treatment market share?
Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 5: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 6: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 7: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY AGE GROUP IN 8 MAJOR MARKETS (2018 – 2027)
Exhibit 8: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN US (2018 – 2027)
Exhibit 9: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN US (2018 – 2020)
Exhibit 10: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN US (2021 – 2027)
Exhibit 11: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN US (2018 – 2027)
Exhibit 12: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY AGE GROUP IN US (2018 – 2027)
Exhibit 13: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN US (2018 – 2027)
Exhibit 14: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY AGE GROUP IN US (2018 – 2027)
Exhibit 15: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN CHINA (2018 – 2027)
Exhibit 16: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN CHINA (2018 – 2020)
Exhibit 17: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN CHINA (2021 – 2027)
Exhibit 18: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN CHINA (2018 – 2027)
Exhibit 19: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY AGE GROUP IN CHINA (2018 – 2027)
Exhibit 20: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN CHINA (2018 – 2027)
Exhibit 21: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY AGE GROUP IN CHINA (2018 – 2027)
Exhibit 22: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN JAPAN (2018 – 2027)
Exhibit 23: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN JAPAN (2018 – 2020)
Exhibit 24: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN JAPAN (2021 – 2027)
Exhibit 25: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN JAPAN (2018 – 2027)
Exhibit 26: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY AGE GROUP IN JAPAN (2018 – 2027)
Exhibit 27: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN JAPAN (2018 – 2027)
Exhibit 28: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY AGE GROUP IN JAPAN (2018 – 2027)
Exhibit 29: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN GERMANY (2018 – 2027)
Exhibit 30: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN GERMANY (2018 – 2020)
Exhibit 31: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN GERMANY (2021 – 2027)
Exhibit 32: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN GERMANY (2018 – 2027)
Exhibit 33: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY AGE GROUP IN GERMANY (2018 – 2027)
Exhibit 34: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN GERMANY (2018 – 2027)
Exhibit 35: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY AGE GROUP IN GERMANY (2018 – 2027)
Exhibit 36: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN UK (2018 – 2027)
Exhibit 37: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN UK (2018 – 2020)
Exhibit 38: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN UK (2021 – 2027)
Exhibit 39: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN UK (2018 – 2027)
Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY AGE GROUP IN UK (2018 – 2027)
Exhibit 41: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN UK (2018 – 2027)
Exhibit 42: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY AGE GROUP IN UK (2018 – 2027)
Exhibit 43: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN FRANCE (2018 – 2027)
Exhibit 44: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN FRANCE (2018 – 2020)
Exhibit 45: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN FRANCE (2021 – 2027)
Exhibit 46: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN FRANCE (2018 – 2027)
Exhibit 47: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY AGE GROUP IN FRANCE (2018 – 2027)
Exhibit 48: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN FRANCE (2018 – 2027)
Exhibit 49: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY AGE GROUP IN FRANCE (2018 – 2027)
Exhibit 50: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN ITALY (2018 – 2027)
Exhibit 51: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN ITALY (2018 – 2020)
Exhibit 52: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN ITALY (2021 – 2027)
Exhibit 53: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN ITALY (2018 – 2027)
Exhibit 54: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY AGE GROUP IN ITALY (2018 – 2027)
Exhibit 55: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN ITALY (2018 – 2027)
Exhibit 56: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY AGE GROUP IN ITALY (2018 – 2027)
Exhibit 57: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN SPAIN (2018 – 2027)
Exhibit 58: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN SPAIN (2018 – 2020)
Exhibit 59: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ATOPIC DERMATITIS IN SPAIN (2021 – 2027)
Exhibit 60: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN SPAIN (2018 – 2027)
Exhibit 61: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ATOPIC DERMATITIS BY AGE GROUP IN SPAIN (2018 – 2027)
Exhibit 62: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY SEVERITY TYPE IN SPAIN (2018 – 2027)
Exhibit 63: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ATOPIC DERMATITIS BY AGE GROUP IN SPAIN (2018 – 2027)
Exhibit 64: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 65: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2018 – 2020)
Exhibit 66: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 67: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 68: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY SEVERITY IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 69: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY AGE GROUP IN 8 MAJOR MARKETS (2021 – 2027)
Exhibit 70: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET IN US (2021 – 2027)
Exhibit 71: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET SNAPSHOT IN US (2018 – 2020)
Exhibit 72: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY DRUG CLASS IN US (2021 – 2027)
Exhibit 73: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY GENDER TYPE IN US (2021 – 2027)
Exhibit 74: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY SEVERITY IN US (2021 – 2027)
Exhibit 75: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY AGE GROUP IN US (2021 – 2027)
Exhibit 76: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET IN CHINA (2021 – 2027)
Exhibit 77: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET SNAPSHOT IN CHINA (2018 – 2020)
Exhibit 78: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2021 – 2027)
Exhibit 79: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2021 – 2027)
Exhibit 80: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY SEVERITY IN CHINA (2021 – 2027)
Exhibit 81: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY AGE GROUP IN CHINA (2021 – 2027)
Exhibit 82: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET IN GERMANY (2021 – 2027)
Exhibit 83: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2018 – 2020)
Exhibit 84: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2021 – 2027)
Exhibit 85: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2021 – 2027)
Exhibit 86: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY SEVERITY IN GERMANY (2021 – 2027)
Exhibit 87: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY AGE GROUP IN GERMANY (2021 – 2027)
Exhibit 88: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET IN JAPAN (2021 – 2027)
Exhibit 89: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2018 – 2020)
Exhibit 90: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2021 – 2027)
Exhibit 91: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2021 – 2027)
Exhibit 92: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY SEVERITY IN JAPAN (2021 – 2027)
Exhibit 93: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY AGE GROUP IN JAPAN (2021 – 2027)
Exhibit 94: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET IN FRANCE (2021 – 2027)
Exhibit 95: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2018 – 2020)
Exhibit 96: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2021 – 2027)
Exhibit 97: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2021 – 2027)
Exhibit 98: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY SEVERITY IN FRANCE (2021 – 2027)
Exhibit 99: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY AGE GROUP IN FRANCE (2021 – 2027)
Exhibit 100: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET IN ITALY (2021 – 2027)
Exhibit 101: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET SNAPSHOT IN ITALY (2018 – 2020)
Exhibit 102: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2021 – 2027)
Exhibit 103: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2021 – 2027)
Exhibit 104: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY SEVERITY IN ITALY (2021 – 2027)
Exhibit 105: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY AGE GROUP IN ITALY (2021 – 2027)
Exhibit 106: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET IN UK (2021 – 2027)
Exhibit 107: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET SNAPSHOT IN UK (2018 – 2020)
Exhibit 108: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY DRUG CLASS IN UK (2021 – 2027)
Exhibit 109: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY GENDER TYPE IN UK (2021 – 2027)
Exhibit 110: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY SEVERITY IN UK (2021 – 2027)
Exhibit 111: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY AGE GROUP IN UK (2021 – 2027)
Exhibit 112: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET IN SPAIN (2021 – 2027)
Exhibit 113: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2018 – 2020)
Exhibit 114: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2021 – 2027)
Exhibit 115: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2021 – 2027)
Exhibit 116: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY SEVERITY IN SPAIN (2021 – 2027)
Exhibit 117: HISTORIC & PROJECTED REVENUE OF ATOPIC DERMATITIS THERAPEUTICS MARKET BY AGE GROUP IN SPAIN (2021 – 2027)
Exhibit 118: MARKETED DRUGS OVERVIEW IN ATOPIC DERMATITIS MARKET
Exhibit 119: MARKETED DRUGS OVERVIEW SNAPSHOT IN ATOPIC DERMATITIS TREATMENT
Exhibit 120: PIPELINE DRUGS OVERVIEW IN ATOPIC DERMATITIS MARKET
Exhibit 121: ATOPIC DERMATITIS PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
Exhibit 122: ATOPIC DERMATITIS PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
Exhibit 123: ATOPIC DERMATITIS PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
Exhibit 124: ATOPIC DERMATITIS PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
Exhibit 125: ATOPIC DERMATITIS PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
Exhibit 126: ATOPIC DERMATITIS PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
Exhibit 127: ATOPIC DERMATITIS CLINICAL TRIAL ANALYSIS SNAPSHOT
Exhibit 128: ATOPIC DERMATITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS
Exhibit 129: ATOPIC DERMATITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE
Exhibit 130: ATOPIC DERMATITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION
Exhibit 131: ATOPIC DERMATITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE
Exhibit 132: ATOPIC DERMATITIS CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE
Exhibit 133: COMPETITIVE ASSESSMENT OF ATOPIC DERMATITIS THERAPEUTICS MARKET
LIST OF TABLES
Table 1: KEY MARKET DRIVERS IN ATOPIC DERMATITIS MARKET
Table 2: KEY MARKET CONSTRAINTS IN ATOPIC DERMATITIS MARKET
Table 3: KEY MARKET TRENDS IN ATOPIC DERMATITIS MARKET
Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUGS IN ATOPIC DERMATITIS
Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN ATOPIC DERMATITIS
Table 6: KEY MILESTONES IN ATOPIC DERMATITIS MARKET
Table 7: KEY DEALS & COLLABORATIONS IN ATOPIC DERMATITIS MARKET
Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN ATOPIC DERMATITIS TREATMENT
1. ATOPIC DERMATITIS OVERVIEW
1.1. Atopic Dermatitis Disease – An Overview
2. ATOPIC DERMATITIS EPIDEMIOLOGY & OVERVIEW
2.1. 8MM: Historic & Projected Volume of Incidence & Prevalence of Atopic Dermatitis
2.2. 8MM: Comparative Analysis of Incidence & Prevalence of Atopic Dermatitis
2.3. 8MM: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Severity Type
2.4. 8MM: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.5. 8MM: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Severity Type
2.6. 8MM: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.7. US: Historic & Projected Volume of Incidence & Prevalence of Atopic Dermatitis
2.8. US: Comparative Analysis of Incidence & Prevalence of Atopic Dermatitis
2.9. US: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Severity Type
2.10. US: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.11. US: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Severity Type
2.12. US: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.13. China: Historic & Projected Volume of Incidence & Prevalence of Atopic Dermatitis
2.14. China: Comparative Analysis of Incidence & Prevalence of Atopic Dermatitis
2.15. China: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Severity Type
2.16. China: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.17. China: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Severity Type
2.18. China: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.19. Japan: Historic & Projected Volume of Incidence & Prevalence of Atopic Dermatitis
2.20. Japan: Comparative Analysis of Incidence & Prevalence of Atopic Dermatitis
2.21. Japan: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Severity Type
2.22. Japan: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.23. Japan: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Severity Type
2.24. Japan: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.25. Germany: Historic & Projected Volume of Incidence & Prevalence of Atopic Dermatitis
2.26. Germany: Comparative Analysis of Incidence & Prevalence of Atopic Dermatitis
2.27. Germany: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Severity Type
2.28. Germany: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.29. Germany: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Severity Type
2.30. Germany: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.31. UK: Historic & Projected Volume of Incidence & Prevalence of Atopic Dermatitis
2.32. UK: Comparative Analysis of Incidence & Prevalence of Atopic Dermatitis
2.33. UK: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Severity Type
2.34. UK: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.35. UK: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Severity Type
2.36. UK: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.37. France: Historic & Projected Volume of Incidence & Prevalence of Atopic Dermatitis
2.38. France: Comparative Analysis of Incidence & Prevalence of Atopic Dermatitis
2.39. France: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Severity Type
2.40. France: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.41. France: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Severity Type
2.42. France: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.43. Italy: Historic & Projected Volume of Incidence & Prevalence of Atopic Dermatitis
2.44. Italy: Comparative Analysis of Incidence & Prevalence of Atopic Dermatitis
2.45. Italy: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Severity Type
2.46. Italy: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.47. Italy: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Severity Type
2.48. Italy: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
2.49. Spain: Historic & Projected Volume of Incidence & Prevalence of Atopic Dermatitis
2.50. Spain: Comparative Analysis of Incidence & Prevalence of Atopic Dermatitis
2.51. Spain: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Severity Type
2.52. Spain: Historic & Projected Volume of Incidence of Atopic Dermatitis cases by Age Group
2.53. Spain: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Severity Type
2.54. Spain: Historic & Projected Volume of Prevalence of Atopic Dermatitis cases by Age Group
3. ATOPIC DERMATITIS MARKET SIZE & OVERVIEW
3.1. 8MM: Historic & Projected Revenue of Atopic Dermatitis
3.2. 8MM: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.3. 8MM: Major Approved Drugs in Atopic Dermatitis
3.4. 8MM: Historic & Projected Revenue Segmentation by Gender Type, Severity, Age Group & Drug Class
3.5. US: Historic & Projected Revenue of Atopic Dermatitis
3.6. US: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.7. US: Historic & Projected Revenue Segmentation by Gender Type, Severity, Age Group & Drug Class
3.8. China: Historic & Projected Revenue of Atopic Dermatitis
3.9. China: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.10. China: Historic & Projected Revenue Segmentation by Gender Type, Severity, Age Group & Drug Class
3.11. Germany: Historic & Projected Revenue of Atopic Dermatitis
3.12. Germany: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.13. Germany: Historic & Projected Revenue Segmentation by Gender Type, Severity, Age Group & Drug Class
3.14. Japan: Historic & Projected Revenue of Atopic Dermatitis
3.15. Japan: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.16. Japan: Historic & Projected Revenue Segmentation by Gender Type, Severity, Age Group & Drug Class
3.17. France: Historic & Projected Revenue of Atopic Dermatitis
3.18. France: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.19. France: Historic & Projected Revenue Segmentation by Gender Type, Severity, Age Group & Drug Class
3.20. Italy: Historic & Projected Revenue of Atopic Dermatitis
3.21. Italy: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.22. Italy: Historic & Projected Revenue Segmentation by Gender Type, Severity, Age Group & Drug Class
3.23. UK: Historic & Projected Revenue of Atopic Dermatitis
3.24. UK: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.25. UK: Historic & Projected Revenue Segmentation by Gender Type, Severity, Age Group & Drug Class
3.26. Spain: Historic & Projected Revenue of Atopic Dermatitis
3.27. Spain: Historic & Projected Revenue of Atopic Dermatitis Snapshot
3.28. Spain: Historic & Projected Revenue Segmentation by Gender Type, Severity, Age Group & Drug Class
4. ATOPIC DERMATITIS MARKETED DRUGS OVERVIEW
4.1. Atopic Dermatitis Marketed Drugs – An Overview
4.2. Atopic Dermatitis Marketed Drugs – Summary
5. ATOPIC DERMATITIS PIPELINE DRUGS OVERVIEW
5.1. Atopic Dermatitis Pipeline Drugs – An Overview
5.2. Atopic Dermatitis Pipeline Drugs – Snapshot
5.3. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Disease type
5.4. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Development Phase
5.5. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Route of Administration
5.6. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Mechanism of Action
5.7. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Molecule type
5.8. Atopic Dermatitis Pipeline Drugs Overview & Snapshot – By Geography type
6. ATOPIC DERMATITIS CLINICAL TRIALS OVERVIEW
6.1. Atopic Dermatitis Clinical Trials Overview Snapsho
6.2. Atopic Dermatitis Clinical Trials Overview – By Recruitment Status
6.3. Atopic Dermatitis Clinical Trials Overview – By Product type
6.4. Atopic Dermatitis Clinical Trials Overview – By Route of Administration
6.5. Atopic Dermatitis Clinical Trials Overview – By Molecule type
6.6. Atopic Dermatitis Clinical Trials Overview – By Geography type
7. ATOPIC DERMATITIS MARKET DYNAMICS
7.1. Atopic Dermatitis Therapeutics Market Drivers
7.2. Atopic Dermatitis Therapeutics Market Constraints
7.3. Atopic Dermatitis Therapeutics Market Trends
8. ATOPIC DERMATITIS COMPETITIVE LANDSCAPE
8.1. Atopic Dermatitis Competitive Landscape – Marketed Drugs
8.2. Key Company Profiles
8.3. Other Key Company Profiles
8.4. Competitive Scenario of Atopic Dermatitis therapeutics market
8.5. Key Company Overviews
8.6. Atopic Dermatitis Competitive Landscape – Pipeline Drugs
8.7. Key Emerging Company Profiles
8.8. Other Key Emerging Company Profiles
8.9. Key Company Overviews
9. ATOPIC DERMATITIS MISCELLANEOUS
9.1. Key Tentative Drug Approvals Timeline
9.2. Key Regulatory Designations
9.3. Key Milestones
9.4. Deals & Collaborations
9.5. Inactive/Discontinued/Dormant Products
10. APPENDIX
10.1. About Arizton
10.2. Research Methodology
10.3. List of Abbreviations
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
How big is the global atopic dermatitis treatment market?
What is the growth rate of the global atopic dermatitis treatment market?
What factors drive the growth of the atopic dermatitis treatment market?
Who are the leading vendors operating in the global atopic dermatitis treatment market?
Which region holds the largest global atopic dermatitis treatment market share?
Other RELATED Reports
 Treatment Market Forecast – Epidemiology & Pipeline Analysis 2022-2027-1649960721.png)
Graft Versus Host Disease Treatment Market Forecast – Epidemiology & Pipeline Analysis 2022-2027
Published : May 2022
Ulcerative Colitis Market Forecast - Epidemiology & Pipeline Analysis 2022-2027
Published : August 2022
Crohn’s Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis
Published : September 2022
Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027
Published : October 2022